RT Book, Section A1 Grosser, Tilo A1 Ricciotti, Emanuela A1 FitzGerald, Garret A. A2 Brunton, Laurence L. A2 Knollmann, Björn C. SR Print(0) ID 1202094989 T1 Pharmacotherapy of Inflammation, Fever, Pain, and Gout T2 Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 14th Edition YR 2023 FD 2023 PB McGraw-Hill Education PP New York, NY SN 9781264258079 LK accessmedicine.mhmedical.com/content.aspx?aid=1202094989 RD 2024/10/14 AB Content UpdateJuly 19, 2023Colchicine for Prevention of Cardiovascular Disease?: Recent clinical trials suggest that low-dose colchicine is a safe, cost-effective adjunct to stain therapy for secondary prevention of ASCVD. In June 2023, the FDA approved the use of low-dose colchicine (0.5 mg once daily) to reduce the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or multiple risk factors for cardiovascular disease. The many on-going and planned clinical trials will likely provide additional evidence needed to guide therapeutic recommendations and guidelines for the cardiovascular application of a drug that has been used for many years to treat non-cardiovascular inflammatory disorders.